425: ARCA biopharma to Merge with Oruka Therapeutics, Creating Dermatology-Focused Company

ARCA biopharma and Oruka Therapeutics have announced a merger agreement to form a company focused on developing novel biologics for chronic skin diseases, supported by a $275 million pre-closing private financing.

Summary

• ARCA biopharma and Oruka Therapeutics have entered into a definitive merger agreement to create a company focused on advancing Orukas pipeline of biologics for chronic skin diseases.
• The combined company will operate as Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol ORKA.
• Oruka has secured commitments for a $275 million pre-closing private investment to fund operations through 2027.
• ARCA expects to declare a cash dividend to pre-merger ARCA stockholders equal to the amount by which ARCAs net cash exceeds $5 million.
• Pre-merger ARCA stockholders are expected to own approximately 2.38% of the combined company, while pre-merger Oruka stockholders will own approximately 97.62%.
• The merger is expected to close in the third quarter of 2024, pending stockholder approval and regulatory conditions.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting the potential of the merger and Orukas pipeline. The financing provides a strong foundation for future development. However, there are inherent risks associated with drug development and regulatory approvals.

Positives

• The merger creates a focused entity with a promising dermatology pipeline.
• The $275 million financing provides substantial runway for clinical development.
• Orukas lead programs, ORKA-001 and ORKA-002, have the potential to be best-in-class biologics.
• The combined company will be led by an experienced management team.
• The merger offers ARCA stockholders the potential for value creation through the Oruka pipeline and a cash dividend.

Negatives

• ARCA stockholders will own a small percentage (approximately 2.38%) of the combined company.
• The merger is subject to stockholder approval and other closing conditions, creating potential for deal failure.

Risks

• The merger may not close if stockholder approval or other conditions are not met.
• Clinical trials for ORKA-001 and ORKA-002 may not be successful.
• The combined company may face challenges in developing and commercializing its pipeline.
• Competition in the dermatology market is intense.
• The combined company may require additional funding in the future.

Future Outlook

The combined company will focus on advancing Orukas pipeline of potentially best-in-class biologics, including ORKA-001 and ORKA-002, with clinical trials expected to begin in 2025. The company anticipates having sufficient resources to fund operations through 2027.

Management Comments

• Lawrence Klein, PhD, Chief Executive Officer of Oruka, stated that the merger and financing are expected to provide resources to build operational capabilities and propel programs into clinical development.
• Robert E. Conway, Chairman of the Board of Directors of ARCA, stated that the combination with Oruka is the best path forward for ARCA stockholders and provides the potential for significant value creation.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation and specialization. Orukas focus on dermatology aligns with the growing market for biologics targeting chronic skin diseases.

Comparison to Industry Standards

• ORKA-001 is being developed as a potentially best-in-class IL-23p19 inhibitor, competing with existing drugs like Skyrizi (risankizumab) from AbbVie.
• ORKA-002 is being developed as a potentially best-in-class IL-17A/F inhibitor, competing with existing drugs like Bimzelx (bimekizumab) from UCB.
• The goal is to achieve higher PASI 100 rates and longer dosing intervals compared to existing therapies.
• The KNOCKOUT study is referenced as evidence that higher IL-23 inhibition can lead to higher response rates.
• The company aims to replicate the success of Apogee Therapeutics and Spyre Therapeutics, which were also founded based on assets generated by Paragon Therapeutics.

Management Changes

Stakeholder Impact

• ARCA stockholders may benefit from the potential value creation of the Oruka pipeline and a cash dividend.
• Oruka stockholders will gain access to the public markets and additional capital.
• Patients with chronic skin diseases may benefit from the development of new and improved therapies.

Next Steps

• Obtain stockholder approval from both ARCA and Oruka.
• File a registration statement with the SEC.
• Complete the $275 million pre-closing private investment.
• Close the merger transaction in the third quarter of 2024.
• Advance ORKA-001 and ORKA-002 into clinical trials in 2025.

Key Dates